February 22, 2021 04:57 PM ESTUpdated February 25, 04:57 AM
Pharma
FDA+

Lib­tayo scores sec­ond OK in two weeks, this time for front-line NSCLC. Can it take on Keytru­da?

Max Gelman

Senior Editor

Com­ing up be­hind the oth­er ma­jor PD-1 play­ers, Re­gen­eron sought to cre­ate its own mar­ket for Lib­tayo by go­ing in­to in­di­ca­tions where oth­ers have yet …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times